GlaxoSmithKline reported its fourth quarter results today which saw sales grow backed by strong growth in vaccines and dermatology segments. The company, which launched its key vaccine for pneumococcal diseases last quarter in India is geared up for more such product launches in 2012. GSK India's managing director, Hasit Joshipura, spoke to CNBC-TV18's Archana Shukla about the company's growth drivers and plans.
Below is the transcript of his comments. Also watch the accompanying video. Q: Can you give us an idea of the growth in vaccines and dermatology segments that pushed sales for you?A: Vaccines have grown upwards of 35% plus for the year. Dermatology has done well and our specialty products have done well too. So I think we have seen growth across the board. Q: Synflorix has been a key launch for the company. What
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
